Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
XRAY Stock Summary
In the News
Here's Why Dentsply International (XRAY) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Dentsply International (XRAY) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Dentsply (XRAY) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Dentsply (XRAY) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
DENTSPLY SIRONA (XRAY) Q4 Earnings Beat Estimates, Sales Up Y/Y
DENTSPLY SIRONA's (XRAY) Q4 revenues improve year over year. Challenging macro headwinds linger.
Dentsply International (XRAY) Q4 Earnings and Revenues Beat Estimates
Dentsply International (XRAY) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.46 per share a year ago.
What's in Store for DENTSPLY SIRONA (XRAY) in Q4 Earnings?
DENTSPLY SIRONA's (XRAY) fourth-quarter 2023 results are likely to reflect a recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.
Will Dentsply (XRAY) Beat Estimates Again in Its Next Earnings Report?
Dentsply (XRAY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Dentsply Sirona to Host Fourth Quarter and Full Year 2023 Conference Call on February 29th
CHARLOTTE, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Thursday, February 29, 2024, at 8:30 am ET to review its fourth quarter and full year 2023 financial results. A presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com.
Dentsply Sirona to Present at J.P. Morgan Healthcare Conference, Provides Update on Anticipated Full Year 2023 Results
CHARLOTTE, N.C., Jan. 09, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 7:30 am PT (10:30 am ET). As part of the conference, the Company is providing an update on its 2023 full year anticipated financial results, with net sales expected to be at or above the high end of the Company's previously provided outlook range of $3.90 billion to $3.94 billion. For the full year and fourth quarter 2023, the Company expects to report year-over-year net sales growth in the Essential Dental Solutions, Wellspect Healthcare, and Orthodontic and Implant Solutions segments, partially offset by declines in the Connected Technology Solutions segment. The Company is reaffirming its full year 2023 adjusted EPS outlook range of $1.80 to $1.85 and its expectations for double-digit adjusted EPS growth in 2024. The Company does not provide forward-looking or preliminary estimates of adjusted EPS on a GAAP basis as certain information needed to prepare adjustments is not yet available and cannot be reasonably estimated. A description of the adjustments typically made to compute adjusted EPS can be found in Exhibit 99.1 to the Company's Current Report on Form 8-K filed on November 2, 2023.
Dentsply Sirona to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Charlotte, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the 42nd Annual J.P. Morgan Healthcare Conference. Management is scheduled to present on Wednesday, January 10, 2024, at 7:30 am PT (10:30 am ET).
XRAY Financial details
XRAY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 18.06 | 15.25 | 19.46 | 18.21 | 18.7 | |
Net income per share | 1.18 | -0.38 | 1.88 | -4.41 | -0.62 | |
Operating cash flow per share | 2.84 | 2.9 | 3.01 | 2.4 | 1.78 | |
Free cash flow per share | 2.29 | 2.5 | 2.36 | 1.71 | 1.08 | |
Cash per share | 1.99 | 2.15 | 1.65 | 1.81 | 1.58 | |
Book value per share | 22.84 | 22.67 | 23.09 | 17.7 | 15.53 | |
Tangible book value per share | -2.14 | -6.93 | -5.73 | -3.62 | -4 | |
Share holders equity per share | 22.84 | 22.67 | 23.09 | 17.7 | 15.53 | |
Interest debt per share | 7.1 | 11.2 | 10.51 | 9.99 | 10.56 | |
Market cap | 12.63B | 11.48B | 12.18B | 6.86B | 7.55B | |
Enterprise value | 13.78B | 13.45B | 14.09B | 8.59B | 9.51B | |
P/E ratio | 48.02 | -138.28 | 29.65 | -7.22 | -57.16 | |
Price to sales ratio | 3.13 | 3.43 | 2.87 | 1.75 | 1.9 | |
POCF ratio | 19.95 | 18.07 | 18.55 | 13.27 | 20.01 | |
PFCF ratio | 24.76 | 20.94 | 23.66 | 18.64 | 33.09 | |
P/B Ratio | 2.48 | 2.31 | 2.42 | 1.8 | 2.29 | |
PTB ratio | 2.48 | 2.31 | 2.42 | 1.8 | 2.29 | |
EV to sales | 3.42 | 4.02 | 3.31 | 2.19 | 2.4 | |
Enterprise value over EBITDA | 16.3 | 17.02 | 14.06 | 13.54 | 14.91 | |
EV to operating cash flow | 21.77 | 21.18 | 21.44 | 16.61 | 25.23 | |
EV to free cash flow | 27.02 | 24.54 | 27.35 | 23.33 | 41.71 | |
Earnings yield | 0.02 | -0.01 | 0.03 | -0.14 | -0.02 | |
Free cash flow yield | 0.04 | 0.05 | 0.04 | 0.05 | 0.03 | |
Debt to equity | 0.31 | 0.48 | 0.44 | 0.55 | 0.66 | |
Debt to assets | 0.18 | 0.26 | 0.24 | 0.27 | 0.29 | |
Net debt to EBITDA | 1.36 | 2.49 | 1.9 | 2.73 | 3.08 | |
Current ratio | 2.01 | 1.36 | 1.55 | 1.62 | 1.38 | |
Interest coverage | 17.77 | 9.5 | 11.31 | 5.1 | 4.61 | |
Income quality | 2.41 | -7.65 | 1.56 | -0.54 | -2.86 | |
Dividend Yield | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | |
Payout ratio | 0.31 | -1.06 | 0.22 | -0.11 | -0.88 | |
Sales general and administrative to revenue | 0 | 0 | 0.36 | 0.41 | 0.41 | |
Research and developement to revenue | 0.03 | 0.03 | 0.04 | 0.04 | 0.05 | |
Intangibles to total assets | 0.65 | 0.69 | 0.68 | 0.6 | 0.56 | |
Capex to operating cash flow | -0.19 | -0.14 | -0.22 | -0.29 | -0.4 | |
Capex to revenue | -0.03 | -0.03 | -0.03 | -0.04 | -0.04 | |
Capex to depreciation | -0.38 | -0.26 | -0.41 | -0.45 | -0.43 | |
Stock based compensation to revenue | 0.02 | 0.01 | 0.01 | 0.02 | 0.01 | |
Graham number | 24.61 | 13.9 | 31.27 | 41.9 | 14.75 | |
ROIC | 0.06 | 0.08 | 0.06 | 0.05 | 0.04 | |
Return on tangible assets | 0.09 | -0.03 | 0.14 | -0.31 | -0.04 | |
Graham Net | -9.84 | -14.43 | -13.75 | -12.32 | -13.5 | |
Working capital | 1B | 474M | 651M | 723M | 548M | |
Tangible asset value | -477.9M | -1.52B | -1.25B | -779M | -849M | |
Net current asset value | -1.51B | -2.58B | -2.34B | -1.94B | -2.1B | |
Invested capital | 0.31 | 0.48 | 0.44 | 0.55 | 0.66 | |
Average receivables | 741.95M | 727.5M | 710M | 689.5M | 694M | |
Average payables | 295.9M | 306.45M | 286.5M | 273.5M | 292M | |
Average inventory | 580.3M | 513.85M | 485M | 565.5M | 625.5M | |
Days sales outstanding | 70.84 | 73.5 | 64.14 | 58.82 | 69.59 | |
Days payables outstanding | 60.29 | 66.07 | 51.76 | 56.73 | 59.34 | |
Days of inventory on hand | 109.98 | 100.94 | 97.33 | 127.5 | 121.41 | |
Receivables turnover | 5.15 | 4.97 | 5.69 | 6.21 | 5.24 | |
Payables turnover | 6.05 | 5.52 | 7.05 | 6.43 | 6.15 | |
Inventory turnover | 3.32 | 3.62 | 3.75 | 2.86 | 3.01 | |
ROE | 0.05 | -0.02 | 0.08 | -0.25 | -0.04 | |
Capex per share | -0.55 | -0.4 | -0.65 | -0.69 | -0.7 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 4.57 | 4.63 | 4.85 | 4.47 | 0.08 | |
Net income per share | -0.07 | -0.11 | 0.41 | -1.26 | 0.32 | |
Operating cash flow per share | 0.66 | -0.1 | 0.49 | 0.63 | 0.76 | |
Free cash flow per share | 0.51 | -0.28 | 0.34 | 0.46 | 0.57 | |
Cash per share | 1.81 | 1.51 | 1.39 | 1.46 | 1.59 | |
Book value per share | 17.72 | 17.25 | 17.47 | 15.92 | 15.68 | |
Tangible book value per share | -3.62 | -4.38 | -3.82 | -3.37 | -4.04 | |
Share holders equity per share | 17.72 | 17.25 | 17.47 | 15.92 | 15.68 | |
Interest debt per share | 9.82 | 10.99 | 10.7 | 10.11 | 10.45 | |
Market cap | 6.85B | 8.29B | 8.48B | 7.24B | 7.47B | |
Enterprise value | 8.58B | 10.28B | 10.43B | 9.05B | 9.44B | |
P/E ratio | -114.15 | -90.14 | 24.65 | -6.8 | 27.89 | |
Price to sales ratio | 6.97 | 8.48 | 8.25 | 7.64 | 467.12 | |
POCF ratio | 48.23 | -394.88 | 81.54 | 53.99 | 46.71 | |
PFCF ratio | 62.26 | -138.21 | 119.44 | 74.59 | 62.28 | |
P/B Ratio | 1.8 | 2.28 | 2.29 | 2.15 | 2.27 | |
PTB ratio | 1.8 | 2.28 | 2.29 | 2.15 | 2.27 | |
EV to sales | 8.73 | 10.51 | 10.15 | 9.56 | 589.93 | |
Enterprise value over EBITDA | 252.26 | 74.47 | 66.02 | 53.54 | 589.93 | |
EV to operating cash flow | 60.4 | -489.35 | 100.3 | 67.53 | 58.99 | |
EV to free cash flow | 77.97 | -171.27 | 146.92 | 93.29 | 78.66 | |
Earnings yield | 0 | 0 | 0.01 | -0.04 | 0.01 | |
Free cash flow yield | 0.02 | -0.01 | 0.01 | 0.01 | 0.02 | |
Debt to equity | 0.55 | 0.63 | 0.61 | 0.63 | 0.66 | |
Debt to assets | 0.27 | 0.3 | 0.29 | 0.29 | 0.29 | |
Net debt to EBITDA | 50.82 | 14.38 | 12.35 | 10.73 | 122.81 | |
Current ratio | 1.62 | 1.41 | 1.51 | 1.57 | 1.38 | |
Interest coverage | -2.37 | 2.84 | 3.81 | -13.11 | 0.8 | |
Income quality | -9.47 | 0.91 | 1.22 | -0.5 | 2.39 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | -1.73 | -1.17 | 0.35 | -0.11 | 0.45 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.04 | 0.05 | 0.05 | 0.05 | 2.69 | |
Intangibles to total assets | 0.6 | 0.59 | 0.59 | 0.57 | 0.56 | |
Capex to operating cash flow | -0.23 | 1.86 | -0.32 | -0.28 | -0.25 | |
Capex to revenue | -0.03 | -0.04 | -0.03 | -0.04 | -2.5 | |
Capex to depreciation | -0.41 | -0.46 | -0.38 | -0.42 | -0.47 | |
Stock based compensation to revenue | 0.01 | 0.02 | 0.01 | 0 | 0.81 | |
Graham number | 5.27 | 6.5 | 12.63 | 21.21 | 10.61 | |
ROIC | 0.01 | 0.01 | 0.02 | -0.04 | 0 | |
Return on tangible assets | 0 | -0.01 | 0.03 | -0.09 | 0.02 | |
Graham Net | -12.34 | -13.73 | -13.32 | -12.79 | -13.63 | |
Working capital | 723M | 569M | 649M | 695M | 548M | |
Tangible asset value | -779M | -925M | -809M | -714M | -849M | |
Net current asset value | -1.94B | -2.09B | -2.03B | -1.92B | -2.1B | |
Invested capital | 0.55 | 0.63 | 0.61 | 0.63 | 0.66 | |
Average receivables | 638.5M | 642M | 661M | 659.5M | 702.5M | |
Average payables | 275M | 273M | 266M | 263.5M | 283.5M | |
Average inventory | 609.5M | 643M | 658M | 654M | 637.5M | |
Days sales outstanding | 57.86 | 60 | 58.66 | 61.68 | 4.25K | |
Days payables outstanding | 53.88 | 52.35 | 49.9 | 52.17 | 56.02 | |
Days of inventory on hand | 121.09 | 129.22 | 123.7 | 129.62 | 114.61 | |
Receivables turnover | 1.56 | 1.5 | 1.53 | 1.46 | 0.02 | |
Payables turnover | 1.67 | 1.72 | 1.8 | 1.73 | 1.61 | |
Inventory turnover | 0.74 | 0.7 | 0.73 | 0.69 | 0.79 | |
ROE | 0 | -0.01 | 0.02 | -0.08 | 0.02 | |
Capex per share | -0.15 | -0.18 | -0.16 | -0.17 | -0.19 |
XRAY Frequently Asked Questions
What is DENTSPLY SIRONA Inc. stock symbol ?
DENTSPLY SIRONA Inc. is a US stock , located in Charlotte of Nc and trading under the symbol XRAY
Is DENTSPLY SIRONA Inc. buy or a sell ?
9 stock analysts have 9 predictions with a medium analyst target price of $50.89. The lowest prediction is $35 and the highest is $75
What is XRAY stock prediction ?
What is DENTSPLY SIRONA Inc. stock quote today ?
DENTSPLY SIRONA Inc. stock price is $33.31 today.
Is DENTSPLY SIRONA Inc. stock public?
Yes, DENTSPLY SIRONA Inc. is a publicly traded company.